 Pharmacor --
February 2006
 Introduction:
Half of men and two-thirds of women who die suddenly of
coronary heart disease (CHD) have no prior symptoms; their subclinical
atherosclerosis is largely undiagnosed and untreated. The most urgent need in
this market is prevention of vulnerable atherosclerotic plaques, which
represents a considerable growth opportunity through 2014.
Questions Answered in This Report:
 The blockbuster statins atorvastatin (Pfizer’s Lipitor) and
simvastatin (Merck’s Zocor) face competition from generic statins during our
forecast period. Will single-pill combinations of atorvastatin or simvastatin
with adjunctive therapies protect the franchises of these branded agents as
generic statins gain approval?
Currently, use of clopidogrel (Sanofi-Aventis/Bristol-Myers Squibb’s
Plavix/Iscover) is confined to PMI patients undergoing percutaneous coronary
intervention (PCI) and to long-term use in aspirin-intolerant patients.
However, new data from the CHARISMA trial are expected in 2006. Will
clopidogrel be able to build on its strong evidence base and achieve greater
usage? Or will it face strong competition from emerging antiplatelet agents?
The EUROPA trial showed that long-term use of perindopril
(Servier’s Coversyl) decreased cardiovascular morbidity and mortality and extended
the knowledge acquired from the earlier HOPE trial of ramipril
(Wyeth/Monarch/King’s Altace, Sanofi-Aventis’s Tritace). Will Servier be able
to capitalize on these favorable results in CHD patients? Or will there be a
general increase in angiotensin-converting enzyme inhibitor (ACEI) use?
Scope:
Markets: United States, France, Germany, Italy,
Spain, United Kingdom, Japan.
Primary research: 33 country-specific interviews with
thought-leading cardiologists.
Epidemiology: Prevalence of asymptomatic CHD;
prevalence of symptomatic CHD: post-myocardial infarction (PMI), stable angina,
and PMI with stable angina.
Patient segments in market forecast: Asymptomatic
CHD; symptomatic CHD (PMI); symptomatic CHD (stable angina); symptomatic CHD
(PMI with stable angina).
Emerging therapies: Phase II: 5 drugs; Phase III: 6
drugs; preregistration: 1 drug; registered: 1 drug.
Market: We forecast drug sales for asymptomatic and
symptomatic patient segments through 2014.
|
